Институт стволовых клеток человека logo
Институт стволовых клеток человека ISKJ

Институт стволовых клеток человека Cash Flow 2007-2026 | ISKJ

Annual Cash Flow Институт стволовых клеток человека

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Net Income

169 M 23.1 M 33.5 M 103 M 111 M -18.2 M -110 M -131 M -62.5 M -16.6 M 16.7 M -142 M 19.2 M 9.47 M 50.1 M 8.57 M 8.04 M

Depreciation And Amortization of Intangible Assets

70.9 M 53.5 M 81.3 M 74.9 M 60 M 29.7 M 40.5 M 24 M 26.2 M 25 M 22.5 M 8.99 M 6.07 M 4.99 M 3.56 M 2.22 M 814 K

Deferred Income Tax

- - - - - - - - - - - - - - - - -

Stock Based Compensation

1.38 M - - - - - - - - - - - - - - - -

Change In Working Capital

-94 M -31.8 M 43.5 M -217 M -87.2 M -45.5 M 43.3 M 163 M 5.44 M 1.57 M 22.7 M -37.6 M 16.9 M -5.42 M 18.4 M 21.8 M -1.86 M

Other Working Capital

- -48.2 M 65 M -111 M -52.4 M -31.5 M 103 M 175 M 6.59 M 37.4 M 26.2 M -32.8 M 14.2 M 516 K 19.2 M 22.5 M -798 K

Other Non Cash Items

288 M 176 M 123 M 92.7 M 91.5 M 53.5 M 6.58 M -20.4 M 35.5 M 28.3 M 20.7 M 144 M -137 K -8.93 M -28.1 M -2.04 M -1.96 M

Investments In Property Plant And Equipment

-204 M -136 M -153 M -85.6 M -196 M -35.3 M -213 M -66.9 M -19.3 M -32.9 M -34.5 M -50.2 M -30.4 M -8.57 M -11 M -19.1 M -7.53 M

Acquisitions Net

- -140 M -71.5 M -107 M - - - - - - -5.59 M - -3.35 M -60.9 M - - -

Purchases Of Investments

- -18.6 M - - - - - - -28.9 M - -22 M -56 M -16.5 M -16.6 M -15.4 M -14.3 M -1.8 M

Sales Maturities Of Investments

- 13.3 M - 121 M 24.1 M 2.8 M 238 K - - 10.5 M 12.6 M - -25.2 M -1.34 M - - 2.67 M

Other Investing Activites

-12.7 M -65.8 M -27.5 M -8.08 M -7.52 M 506 K -277 K 9.97 M 18.2 M -12.4 M -1 K 4.02 M 27 M 10.5 M 2.12 M 2.67 M 748 K

Net Cash Used For Investing Activites

-217 M -347 M -252 M -79.2 M -180 M -32 M -213 M -57 M -30 M -34.8 M -49.5 M -102 M -48.5 M -76.9 M -24.3 M -30.7 M -5.91 M

Debt Repayment

-83.8 M 194 M 142 M 72 M -91.5 M -14.4 M 89 M 295 M 11.8 M -15.1 M -22.6 M 144 M 3.04 M 8 K -3.01 M 2.99 M -382 K

Common Stock Repurchased

- - - - - - - - - - - - -50.3 M - - -300 K -

Dividends Paid

- - - - - - - -21.3 M - - - - - -7.5 M -8.6 M -3.35 M -

Other Financing Activites

209 M -99.4 M -86.3 M -30.9 M 92.4 M -28.9 M -34.1 M -338 M -57.8 M 64.4 M -18.9 M -5.45 M -365 K -302 K -357 K -215 K -40 K

Net Cash Used Provided By Financing Activities

125 M 138 M 59 M 45.1 M 32.4 M -26.1 M 54.9 M 257 M 5.95 M 49.3 M -41.5 M 138 M -46.3 M -7.79 M 131 M -876 K 4.58 M

Effect Of Forex Changes On Cash

460 K -3.46 M -1.61 M -2.18 M -3.16 M -3.64 M -1.21 M -1.11 M - - - - - - - - -1 K

Net Change In Cash

343 M 8.37 M 85.9 M 17.6 M 25.3 M -42.4 M -179 M 235 M -19.5 M 52.7 M -8.55 M 9.31 M -52.7 M -84.6 M 150 M -1.01 M 3.7 M

Cash At End Of Period

545 M 202 M 193 M 107 M 89.7 M 64.4 M 107 M 286 M 51.3 M 70.8 M 18.1 M 26.7 M 17.4 M 70 M 155 M 4.32 M 5.33 M

Cash At Beginning Of Period

202 M 193 M 107 M 89.7 M 64.4 M 107 M 286 M 50.8 M 70.8 M 18.1 M 26.7 M 17.4 M 70 M 155 M 4.32 M 5.33 M 1.63 M

Operating Cash Flow

435 M 220 M 281 M 53.9 M 176 M 19.4 M -19.6 M 36 M 4.6 M 38.2 M 82.5 M -26.6 M 42.1 M 115 K 43.9 M 30.5 M 5.03 M

Capital Expenditure

-204 M -136 M -153 M -85.6 M -196 M -35.3 M -213 M -66.9 M -19.3 M -32.9 M -34.5 M -50.2 M -30.4 M -8.57 M -11 M -19.1 M -7.53 M

Free Cash Flow

231 M 84.4 M 128 M -31.7 M -20.5 M -15.9 M -232 M -30.9 M -14.7 M 5.37 M 48 M -76.8 M 11.7 M -8.46 M 33 M 11.5 M -2.5 M

All numbers in RUB currency

Quarterly Cash Flow Институт стволовых клеток человека

2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3

Net Income

41.5 M 41.5 M 68.5 M 68.5 M 15.9 M 15.9 M 10.6 M 10.6 M 12.5 M 12.5 M -8.08 B -4.04 M 19.7 B 9.86 M 19.7 B 208 K 417 M 36.2 M 72.4 B 16.6 M 25.7 M 25.7 M -33.7 M -33.7 M 16.6 M 16.6 M -78.9 M 25.2 M -24.4 M -19.9 M -12.2 M -48.4 M -56.1 M -7.16 M -34 M -34 M 8.19 M 8.19 M -23.3 M -23.3 M 16.7 M 16.7 M -13 M -13 M

Depreciation And Amortization of Intangible Assets

19.8 M 19.8 M 13.4 M 13.4 M 22.1 M 22.1 M 9.5 M 9.5 M 17.2 M 17.2 M 44.5 B 22.2 M 36.8 B 18.4 M - 19.9 M - 17.6 M - 14.5 M 15.5 M 15.5 M 2.25 M 2.25 M 12.6 M 12.6 M 20.8 M 9.2 M 603 K 9.86 M 5.18 M 7.82 M 4.44 M 6.55 M 6.78 M 6.78 M 6.32 M 6.32 M 5.66 M - 6.84 M - 5.9 M -

Deferred Income Tax

- - - - - - - - - - -5.04 B - -5.05 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Stock Based Compensation

325 K 325 K 328 K 328 K 362 K 362 K 587 K 587 K 4.13 M 4.13 M - 5.66 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Change In Working Capital

-49.7 M -49.7 M 332 K 332 K -47.3 M -47.3 M 67 M 67 M -15.5 M -15.5 M 83.4 B 13.5 M -39.9 B -19.9 M - 4.5 M - -117 M - 9.96 M -35.3 M -35.3 M -28.6 M -28.6 M 15.1 M 15.1 M 105 M -53.1 M 3.62 M -24.3 M 160 M -5.66 M 16.2 M -24.5 M -13.1 M -13.1 M -12.1 M -12.1 M -26.5 M - 10.4 M - 722 K -

Other Working Capital

- - - - - - - - - - - - - - - - - - - - - - - - - - 112 M -4.53 M - - 165 M -9.07 M - - - - - - - - - - -577 K -

Other Non Cash Items

44.6 M 44.6 M 109 M 109 M 35.2 M 35.2 M -1.22 M -1.22 M 5.31 M 5.31 M -115 B 76.3 M -11.6 B 18.4 M -19.7 B 37.2 M -417 M 27.9 M -72.4 B 35.3 M 9.3 M 9.3 M 29.5 M 29.5 M -4.04 M -4.04 M -6.16 M 5.79 M 343 K 6.95 M -12.3 M -36.9 M 37.3 M 1.42 M 65.1 M 65.1 M -24.9 M -24.9 M 30.1 M 23.3 M -758 K -16.7 M 14 M 13 M

Investments In Property Plant And Equipment

-29.3 M -29.3 M -69.4 M -69.4 M -32.7 M -32.7 M -19.3 M -19.3 M -48.7 M -48.7 M -143 B -49.9 M -53.6 B -26.8 M - -18.3 M - -24.5 M - -82.8 M -4.02 M -4.02 M 27.7 M 27.7 M -45.4 M -45.4 M -16.3 M -51.1 M -130 M -15.4 M -51.2 M -6.81 M -8.91 M - -6.26 M -6.26 M -3.39 M -3.39 M -11.7 M - -4.68 M - 9.21 M -

Acquisitions Net

- - -125 K -125 K 125 K 125 K -39.5 M -39.5 M - - - - - - - -35.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Purchases Of Investments

- - - - - - - - - - -50.2 B - -21.3 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Sales Maturities Of Investments

- - - - - - - - - - - - - - - - - - - - - - - - - - -33 K 162 K - - - 22.6 M - - - - - - - - - - - -

Other Investing Activites

11 M 11 M -2.36 M -2.36 M -3.98 M -3.98 M -49.3 M -49.3 M -16.6 M -16.6 M 13.4 B -39.1 M 8.94 B -10.4 M - 4.77 M - 33.6 M - 7.12 M 1.2 M 1.2 M 170 K 170 K 1.48 M 1.48 M -23.7 M -50.4 M 3.15 M 3.4 M - 414 K 20.7 M 4.54 M -17.9 M -17.9 M 12.6 M 12.6 M 15.7 M - -16.7 M - -1.89 M -

Net Cash Used For Investing Activites

-18.3 M -18.3 M -71.9 M -71.9 M -36.6 M -36.6 M -108 M -108 M -65.3 M -65.3 M -180 B -88.9 M -65.9 B -37.2 M - -48.7 M - 9.12 M - -75.7 M -2.82 M -2.82 M 27.9 M 27.9 M -43.9 M -43.9 M -23.7 M -50.3 M -127 M -12 M -96.3 M 23 M 11.8 M 4.54 M -24.2 M -24.2 M 9.17 M 9.17 M 3.98 M - -21.4 M - 7.33 M -

Debt Repayment

- - - - - - - - - - - - - - - - - - - - - - - - - - -5.5 M -3.5 M 6.5 M 91.5 M -9.08 M 322 M -15.4 M -2.36 M - - - - - - - - - -

Common Stock Repurchased

-11.3 M -11.3 M - - - - - - - - - - - - - -3.47 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Dividends Paid

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Other Financing Activites

-113 M -113 M -27.8 M -27.8 M 90.2 M 90.2 M 93.3 M 93.3 M -24.1 M -24.1 M 127 B 48.1 M -29.5 B -18.6 M - -35 M - 61 M - 14.6 M -13.4 M -13.4 M -3.59 M -3.59 M -9.47 M -9.47 M -12 M -7.42 M -10.1 M -4.55 M -31.3 M -1.97 M -3.89 M -639 K -4.03 M -4.03 M 7.01 M 7.01 M -846 K - 25.5 M - -22.8 M -

Net Cash Used Provided By Financing Activities

-124 M -124 M -27.8 M -27.8 M 90.2 M 90.2 M 93.3 M 93.3 M -24.1 M -24.1 M 127 B 48.1 M -29.5 B -18.6 M - -38.5 M - 61 M - 14.6 M -13.4 M -13.4 M -3.59 M -3.59 M -9.47 M -9.47 M -17.5 M -10.9 M -3.6 M 87 M -40.4 M 320 M -19.3 M -2.99 M -4.03 M -4.03 M 7.01 M 7.01 M -846 K - 25.5 M - -22.8 M -

Effect Of Forex Changes On Cash

-1.61 M -1.61 M 57 K 57 K 173 K 173 K -524 K -524 K -1.21 M -1.21 M - -484 K - -321 K - 57 K - -1.14 M - 241 K -1.82 M -1.82 M -904 K -904 K -917 K -917 K -166 K -453 K -590 K - -520 K - -529 K - -308 K -308 K - - - - - - - -

Net Change In Cash

- - - -362 M 362 M - - -59.4 M 59.4 M - 146 B -48.5 M -58.2 B - - -158 M - - - -58.7 M 58.7 M - - -78.7 M 78.7 M -107 M -863 K -74.6 M -151 M 47.6 M 3.82 M 253 M -6.31 M 28.6 M - -58.2 M 58.2 M - - - - - - -

Cash At End Of Period

- - - - 362 M - - - 59.4 M - 146 B - -58.2 B - - - - - - - 58.7 M - - - 78.7 M - 107 M 108 M 182 M 333 M 286 M 282 M 22.3 M 28.6 M - - 58.2 M - - - - - - -

Cash At Beginning Of Period

- - - 362 M - - - 59.4 M - - - 48.5 M - - - 158 M - - - 58.7 M - - - 78.7 M - 107 M 108 M 182 M 333 M 286 M 282 M 28.6 M 28.6 M - - 58.2 M - - - - - - - -

Operating Cash Flow

56.5 M 56.5 M 191 M 191 M 26.2 M 26.2 M 86.5 M 86.5 M 23.7 M 23.7 M 199 B 114 M 37.1 B 26.7 M - 61.8 M - -34.9 M - 76.3 M 15.2 M 15.2 M -30.5 M -30.5 M 40.2 M 40.2 M 40.5 M -13 M -19.9 M -27.3 M 141 M -83.1 M 1.79 M -23.7 M 24.8 M 24.8 M -22.5 M -22.5 M -14.1 M - 33.2 M - 7.54 M -

Capital Expenditure

-29.3 M -29.3 M -69.4 M -69.4 M -32.7 M -32.7 M -19.3 M -19.3 M -48.7 M -48.7 M -143 B -49.9 M -53.6 B -26.8 M - -18.3 M - -24.5 M - -82.8 M -4.02 M -4.02 M 27.7 M 27.7 M -45.4 M -45.4 M -16.3 M -51.1 M -130 M -15.4 M -51.2 M -6.81 M -8.91 M - -6.26 M -6.26 M -3.39 M -3.39 M -11.7 M - -4.68 M - 9.21 M -

Free Cash Flow

27.2 M 27.2 M 122 M 122 M -6.52 M -6.52 M 67.2 M 67.2 M -25 M -25 M 56 B 63.9 M -16.4 B -106 K - 43.5 M - -59.3 M - -6.44 M 11.2 M 11.2 M -2.84 M -2.84 M -5.12 M -5.12 M 24.2 M -64.1 M -150 M -42.7 M 89.8 M -89.9 M -7.12 M -23.7 M 18.5 M 18.5 M -25.9 M -25.9 M -25.8 M - 28.5 M - 16.8 M -

All numbers in RUB currency

Cash Flow Statement is one of the three key financial reports of the company Институт стволовых клеток человека, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 18.36 -0.78 % $ 2.7 B usaUSA
Amgen Amgen
AMGN
$ 343.69 0.53 % $ 185 B usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 70.78 2.09 % $ 9.47 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Aytu BioScience Aytu BioScience
AYTU
$ 2.66 2.31 % $ 16.7 M usaUSA
Adagene Adagene
ADAG
$ 2.97 8.0 % $ 167 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.14 -0.95 % $ 7.55 B australiaAustralia
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Biogen Biogen
BIIB
$ 179.14 -0.42 % $ 26.1 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.41 -0.35 % $ 264 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 223.85 -1.0 % $ 5 B danmarkDanmark
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.82 1.34 % $ 1.59 B britainBritain
BioNTech SE BioNTech SE
BNTX
$ 110.32 -3.02 % $ 27.2 B germanyGermany
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.39 1.09 % $ 355 M britainBritain
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.72 -1.71 % $ 82 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.13 2.99 % $ 8.99 B israelIsrael
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 14.13 3.25 % $ 4.37 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 6.69 1.6 % $ 1.38 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 27.78 0.58 % $ 2.29 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael